NCT07043166 Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
| NCT ID | NCT07043166 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Changzheng Hospital |
| Condition | Metabolic Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,094 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2035-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,094 participants in total. It began in 2025-07-01 with a primary completion date of 2035-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants. The study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.
Eligibility Criteria
Inclusion Criteria: 1. The 4,094 residents of Shanghai communities who have been enrolled in the STONE cohort. 2. Individuals who completed the baseline questionnaire survey, physical examination, and related clinical tests between 2016 and 2017, with complete data records. 3. Willingness to participate in this follow-up study and provision of informed consent. Exclusion Criteria: 1. Participants who have moved away from their original community and have been living elsewhere for more than two years. 2. Participants whose contact information has changed or become invalid, resulting in loss of contact (those who remain uncontactable after three attempts to reach out).
Contact & Investigator
tuo Li, Prof.
STUDY DIRECTOR
Shanghai Changzheng Hospital
Frequently Asked Questions
Who can join the NCT07043166 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metabolic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07043166 currently recruiting?
Yes, NCT07043166 is actively recruiting participants. Contact the research team at dr.lituo@smmu.edu.cn for enrollment information.
Where is the NCT07043166 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07043166 clinical trial?
NCT07043166 is sponsored by Shanghai Changzheng Hospital. The principal investigator is tuo Li, Prof. at Shanghai Changzheng Hospital. The trial plans to enroll 4,094 participants.